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Abstract
Aims: Activating transcription factor 3 (ATF3) is a stress-activated immediate early gene suggested to have both detrimental
and cardioprotective role in the heart. Here we studied the mechanisms of ATF3 activation by hypertrophic stimuli and
ATF3 downstream targets in rat cardiomyocytes.
Methods and Results: When neonatal rat cardiomyocytes were exposed to endothelin-1 (ET-1, 100 nM) and mechanical
stretching in vitro, maximal increase in ATF3 expression occurred at 1 hour. Inhibition of extracellular signal-regulated
kinase (ERK) by PD98059 decreased ET-1– and stretch–induced increase of ATF3 protein but not ATF3 mRNA levels, whereas
protein kinase A (PKA) inhibitor H89 attenuated both ATF3 mRNA transcription and protein expression in response to ET-1
and stretch. To characterize further the regulatory mechanisms upstream of ATF3, p38 mitogen-activated protein kinase
(MAPK) signaling was investigated using a gain-of-function approach. Adenoviral overexpression of p38a, but not p38b,
increased ATF3 mRNA and protein levels as well as DNA binding activity. To investigate the role of ATF3 in hypertrophic
process, we overexpressed ATF3 by adenovirus-mediated gene transfer. In vitro, ATF3 gene delivery attenuated the mRNA
transcription of interleukin-6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1), and enhanced nuclear factor-kB (NF-kB)
and Nkx-2.5 DNA binding activities. Reduced PAI-1 expression was also detected in vivo in adult rat heart by direct
intramyocardial adenovirus-mediated ATF3 gene delivery.
Conclusions: These data demonstrate that ATF3 activation by ET-1 and mechanical stretch is partly mediated through ERK
and cAMP-PKA pathways, whereas p38 MAPK pathway is involved in ATF3 activation exclusively through p38a isoform.
ATF3 activation caused induction of modulators of the inflammatory response NF-kB and Nkx-2.5, as well as attenuation of
pro-fibrotic and pro-inflammatory proteins IL-6 and PAI-1, suggesting cardioprotective role for ATF3 in the heart.
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Introduction
Most patients with heart failure have a history of left ventricular
hypertrophy, which is initially an adaptive response to increased
work load. However, after sustained external load, hearts can
evolve to a state of decompensated hypertrophy resulting in the
dilatation of the left ventricle and loss of contractile function [1,2].
In response to hypertrophic stimuli, a fundamental reprogram-
ming occurs within the adult cardiomyocytes that results in the
expression of genes encoding fetal protein isoforms. The imme-
diate early genetic response includes transcription of genes such as
c-fos, c-jun and early growth response–1 (EGR-1). Later during
the hypertrophic process, the transcription of contractile proteins,
a-myosin heavy chain (a-MHC) and cardiac a-actin, are down-
regulated and expression of b-MHC and skeletal muscle a-actin
are up-regulated. Also non-contractile proteingenes such as atrial
natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)
become highly expressed within ventricular myocytes [3].
The myocardium can hypertrophy in response to increases in
wall stress as well as to humoral and neural stimuli [4]. Wall
stretch and various other hypertrophic stimuli such as angiotensin
II, endothelin-1 (ET-1), cytokines and growth factors in turn result
in the activation of specific intracellular signalling cascades
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including mitogen-activated protein kinase (MAPK), protein
kinase C (PKC), insulin-like growth factor-1/Akt, and the
calcium-activated protein phosphatase calcineurin [5]. Specifical-
ly, all MAPK pathways – extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinase (JNK) and p38 MAPK – are key
signaling routes in mechanical load–induced hypertrophic process
[6]. These and other intracellular signalling cascades then
modulate transcription factors such as activator protein-1 (AP-1)
[7], GATA-4, Nkx-2.5 and nuclear factor-kB (NF-kB) [8], which
in turn regulate gene expression to facilitate the growth of the
heart activated by mechanical load.
Our DNA microarray study using adenovirus-mediated over-
expression of wild type (WT) p38a and constitutively active
upstream MAP kinase kinase 3b (MKK3b) in vivo identified
several novel p38 MAPK target genes, including activating
transcription factor 3 (ATF3) [12]. ATF3 is a member of the
ATF/cyclicAMP–responsive element-binding (ATF/CREB) fam-
ily of transcription factors. In the heart, ATF3 transcription has
been shown to be induced under oxidative stress (H2O2-treatment)
as well as ischemia/hypoxia and ischemia-reperfusion models both
in vivo and in vitro [9–11]. Recently, administration of pressor
substances angiotensin II and phenylephrine (PE) in mice have
been shown to up-regulate cardiac ATF3 [13–15]. However, the
precise mechanisms regulating ATF3 activation during hypertro-
phic process are not fully understood, and whether mechanical
stretch directly activates ATF3 in the heart is not known.
Moreover, the exact role of ATF3 in the heart is not yet defined
[15–19]. In a very recent study, cardiac overexpression of ATF3 in
mice was sufficient to promote cardiac hypertrophy and exacer-
bate the deleterious effect of chronic pressure overload, while
Table 1. Oligonucleotides for EMSA.
Probe Sequence
AP-1 59- GGAAGTGTTTTTGATGAGTCACCCCA -39
ATF3 59-CTCGATGCCATGACATCATCTTTA-39
NF-kB 59- AGTTGAGGGGACTTTCCCAGGCCA -39
Nkx-2.5 59- AGAGACCTTTGAAGTGGGGGCCTCTTGAGGCCCCG-39
doi:10.1371/journal.pone.0105168.t001
Table 2. Sequences of rat forward (F) and reverse (R) primers and fluorogenic probes used for real time RT-qPCR analysis
(sequences 59 to 39).
Gene Primer Fluorogenic probe
ANP (F) GAAAAGCAAACTGAGGGCTCTG TCGCTGGCCCTCGGAGCCT
(R) CCTACCCCCGAAGCAGCT
ATF-3 (F) TGAAGAATGAGAAGCAGCATCTG TGCTCAACCTGCACCGGCCC
(R) TCTGAGCCCGGAC GATACAC
BMP-2 (F) ACACCGTGCTCAGCTTCCAT ACGAAGAAGCCATCGAGGAACTTTCAGAA
(R) GTCGGGAAGTTTTC CCACTCA
BNP (F) TGGGCAGAAGATAGACCGGA CGGCGCAGTCAGTCGCTTGG
(R) ACAACCTCAGCCC GTCACAG
Ca a-actin (F) GGGCCCTCCATTGTCCA CGCAAGTGCTTCTGAGGCGGCTAC
(R) GCACAATACTGTCGTCCTGAGTG
IL-6 (F) CAGAATTGCCATTGCACAACTCTTTTCTCA TGCATCATCGCTGTTCATACAA
(R) ATATGTTCTCAGGG AGATCTTGGA
a-MHC (F) GCAGAAAATGCACGATGAGGA TAACCTGTCCAGCAGAAAGAGCCTCGC
(R) CATTCATATTTATTGTGGGATAGCAAC
ß-MHC (F) GCTACCCAACCCTAAGGATGC TGTGAAGCCCTGAGACCTGGAGCC
(R) TCTGCCTAAGGTGCTGTTTCAA
OSP (F) AATCGCCCCCACAGTCG TGTCCCTGACGGCCGAGGTGA
(R) CCTCAGTCCGTAAG CCAAGC
PAI-1 (F) GCTGACCACAGCAGGGAAA CCCGGCAGCAGATCCAAGATGCTAT
(R) GTGCCCCTCTCACT GATATTGAA
Sk a-actin (F) TCCTCCGCCGTTGGCT CATCGCCGCCACTGCAGCC
(R)AATCTATGTACACGTCAAAAACAGGC
18S (F) TGGTTGCAAAGCTGAAACTTAAAG CCTGGTGGTGCCCTTCCGTCA
(R) AGTCAAATTAAGCC GCAGGC
doi:10.1371/journal.pone.0105168.t002
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Figure 1. Hypertrophic stimuli induce ATF3 gene expression in cultured NRCM. Cardiomyocyte cell cultures were subjected to ET-1
(100 nM) stimulifor 1, 4, 12 and 24 hours (A, B, D), cyclic mechanical stretch for 1, 4, 12, 24 and 48 hours (C, E), or LPS (1 mg/ml) for 4 hours. ATF3 (A,
C, F) and BNP (D, E) mRNA levels were normalized to 18S quantified from the same samples, and are presented relative to control cells. The results
represent mean 6 SEM (n= 8–18) from at least 3 independent experiments. B, ATF3 protein levels after ET-1 stimuli were determined by Western
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ATF3 knockout mice displayed less cardiac hypertrophy in the
pressure overload model [18].
In the present study we demonstrate that ERK and PKA
pathways are involved in ATF3 activation in response to ET-1
stimulation and mechanical stretching of neonatal rat cardiomy-
ocytes (NRCM), and that the main p38 MAPK isoform upstream
of ATF3 is p38a. We further show that ATF3 overexpression leads
to a decreased rate of protein synthesis, a marker for cardiac
hypertrophy, and is characterized with activation of a suppressor
of inflammation, NF-kB, as well as with activation of a survival
factor Nkx-2.5. In addition, ATF3 overexpression inhibited the
expression of pro-inflammatory protein plasminogen activator
inhibitor-1 (PAI-1) both in vitro and in vivo, as well as the
expression of inflammatory cytokine interleukin-6 (IL-6) in vitro.
Altogether, these data indicate that although induced by
hypertrophic stimuli, the activation of ATF3 might be cardiopro-
tective and contribute to the beneficial, adaptive cardiomyocyte
hypertrophy.
Materials and Methods
Ethics statement
All experimental protocols were approved by the Animal Use
and Care Committee of the University of Oulu and the Provincial
Government of Western Finland Department of Social Affairs and
Health (ESAVI/4365/04.10.03/2011).
blotting and normalized to GAPDH loading control levels. Representative Western blots are shown, and bar graphs represent mean 6 SEM (n= 7)
from 3 independent experiments. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0105168.g001
Figure 2. The effect of ERK and p38 MAPK kinase inhibition on ET-1–induced ATF3 expression. ERK inhibitor PD98059 (10 mM) (A, C) or
p38 inhibitor SB203580 (10 mM) (B, D) were added to culture medium of neonatal rat cardiomyocyte cell cultures and 2 hours later ET-1 (100 nM)
was added to medium for 1 hour. DMSO was used as a control. A, B, ATF3 mRNA levels were determined by qPCR and normalized to 18S quantified
from the same samples. The mRNA levels are presented relative to non-stimulated DMSO control cells. The results represent mean 6 SEM (n= 3–19)
from at least 3 independent experiments. C, D, ATF3 and GAPDH protein levels were detected by Western blotting and representative Western blots
are shown. ATF3 protein levels were normalized with GAPDH levels and are presented relative to non-stimulated DMSO control cells. Bar graphs
represent mean 6 SEM (n = 6–10) from at least 3 independent experiments. ** P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0105168.g002
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Materials
Cell culture reagents (bovine serum albumin, calcium chloride,
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F-12), phosphate buffered saline (PBS), insulin-transfer-
rin sodium-selenite media supplement, L-glutamine, penicillin-
streptomycin, sodium puryvate, 39,39,59-triiodo-L-thyronine), ET-
1, PE, lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate
(PMA), PKA inhibitor H89, protease- and phosphatase- inhibitor
cocktails (used in protein extraction) and protein extraction
detergent IGEPAL CA-630, as well as all the oligonucleotides
were from Sigma-Aldrich (St. Louis, MO, USA). ERK inhibitor
PD98059 and p38 MAPK inhibitor SB203580 were from Tocris
Bioscience (Bristol, UK). Antibodies against ATF3, NF-kB, Nkx-
2.5 and AP-1 were from Santa Cruz Biotechnology Inc (Santa
Cruz, CA, USA). ECL Plus Western Blotting Detection System
reagents, First-Strand cDNA Synthesis Kit and leucine L-[4,5-3H]
were from GE Healthcare (Waukesha, WI, USA). Bio-Rad Protein
Assay was from Bio-Rad Laboratories (Hercules, CA, USA).
Secondary antibodies horseradish peroxidase (HRP)-linked anti-
rabbit IgG and anti-mouse IgG were purchased from Cell
Signaling Technology (Danvers, MA, USA). Antibody for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as well as
collagenase type II Worthington (used in cell culture) was from
Millipore (Billerica, MA, USA). Heat-inactivated fetal bovine
serum (FBS) for cell culture was from Invitrogen (Carlsbad, CA,
USA). Recombinant human acidic fibroblast growth factor (aFGF)
was from R&D systems (Minneapolis, MN, USA). Optitran BA-S
85 nitrocellulose membranes were from Schleicher & Schuell
BioScience (Dassel, Germany). Rigid bottomed cell culture plates
were from Greiner Bio-one (Monroe, NC, USA).
Adenoviruses
Adenoviruses containing the coding regions of rat constitutively
active MKK3b, constitutively active MKK6b, WT p38a, and
replication-deficient adenovirus RAdlacZ were all driven by
cytomegalovirus immediately early promoter. The MKK3b,
MKK6b and WT p38b adenoviruses have been described
previously [20]. The ATF3–overexpressing adenovirus (serotype
5) was generated as previously described [21]. Briefly, a full-length
coding region of ATF3 cDNA was subcloned into the SalI and
HindIII sites of the pShuttle-CMV vector (Qbiogene Inc,
Montreal, Canada). The sequences for the cloning primers used
were as follows; ATF3 forward 59- GCG TCG ACT GGA GCA
AAA TGA TGC TTC AAC-39 and reverse 59- CCC AAG CTT
TTA GCT CTG CAA TGT TCC TTC-39. The pShuttle-CMV-
LacZ was a commercial plasmid (Stratagene, La Jolla, CA, USA).
Adenoviruses were prepared by standard protocols (QbiogeneInc,
Montreal, Canada) and purified by centrifugation on iodixanol
(OptiPrep, Axis-Shield PoC AS, Oslo, Norway). The adenoviral
titers (infectious unit, ifu) were determined by AdEasy Viral Titer
Kit (Stratagene, La Jolla, CA, USA). Infectious unit is biologically
equivalent to plaque forming unit (pfu).
Animals
Newborn, 2- to 4-day-old Sprague-Dawley (SD)- rats of both
sexes and male 2- to 3-month-old Sprague-Dawley (SD) rats
weighing from 250 to 300 g and from the colony of the Centre of
Experimental Animals at the University of Oulu were used.
Cell culture and transfection
Cell cultures of cardiac ventricular cells were prepared from 2-
to-4-day-old Sprague-Dawley -rats using the collagenase dissoci-
ation method [22]. For stretch experiments, the cells were plated
at Collagen type I –coated Bioflex 6-well plates (Flexcell
International Corporation) at a density of 1.66105/cm2 in
serum-containing medium overnight. Thereafter, NRCM were
incubated in complete serum-free medium (CSFM). For experi-
ments with adenoviruses, these were added to the CSFM 18–24 h
after plating at 4 MOI (multiplicity of infection). The experiments
were completed 24 hours after the transduction. When appropri-
ate, ERK inhibitor PD98059, p38 MAPK inhibitor SB203580, or
PKA inhibitor H89 were added to culture medium. Two hours
after the insertion of kinase inhibitors, PE or ET-1 was added to
the culture medium, alternatively the cells were subjected to
mechanical stretch. When appropriate, NRCM were treated with
LPS, PE, PMA or aFGF.
Application of mechanical stretch
The cells were exposed to cyclic mechanical stretch for 1, 4, 12,
24 or 48 hours by applying a computer controlled (Flexercell
Strain Unit FX-3000, Flexcell International Corporation) vacuum
suction under the flexible-bottomed collagen I-coated 6-well cell
culture plates, as previously described [22]. After experiments the
cells were quickly frozen with nitrogen oxide at 270uC.
Cardiac gene transfer in vivo
Adenovirus-mediated intramyocardial gene transfer of ATF3
and LacZ at 16109 pfu into the left ventricle (LV) free wall of male
2-month-old Sprague-Dawley –rats [12]. Three days following the
gene transfer, the animals were sacrificed and LV tissue samples
were stored at 270uC for later analysis. Animals were from the
colony of the Centre for Experimental Animals at the University of
Oulu.
Total protein extraction and Western blotting
Total protein extraction and Western blot analyses were
performed as previously described [22,23] with the exception of
single protease/phosphatase inhibitors being changed to protease-
inhibitor cocktail (1:100 volume), phosphatase-inhibitor cocktail
(1:100 volume) and 1 mM dithiothreitol (DTT) (1:1000 volume).
Proteins were detected by enhanced chemiluminescence reagents
(ECL Plus Western Blotting Detection System) with Fujifilm LAS-
3000 Imager (Fujifilm, Tokyo, Japan). The bands were quantified
with Quantity One software (Bio-Rad Hercules, CA, USA).
Nuclear protein extraction and EMSA
EMSA assay is used to study DNA-protein binding interactions
and qualitatively to identify sequence-specific DNA-binding
proteins. To extract the nuclear and cytosolic proteins from
NRCM cultures, the cells were incubated in low salt buffer
consisting of 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid), 10 mMKCl, 0.1 mM EDTA and
Figure 3. PKA inhibitor H89 inhibits ET-1- and isoprenaline-induced ATF3 increase in NRCM. Cultured cardiomyocytes were treated for
2 hours with PKA inhibitor H89 (1 mM A, B or 10 mM C, D, E) subsequently the cells were subjected to ET-1 (100 nM, 1 h) or isoprenaline (100 nM,
15 min) stimuli. A, C, ATF3 mRNA levels were determined by qPCR and normalized to 18S quantified from the same samples. The mRNA levels are
presented relative to non-stimulated DMSO control cells. The protein levels of ATF3 and GAPDH loading control were detected by Western blotting
(B, D, E). Representative Western blots are shown. Bar graphs represent ATF3 protein levels normalized with GAPDH levels and presented relative to
control group. Mean 6 SEM (n= 5–10) from 3 independent experiments is presented. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0105168.g003
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Figure 4. The effect of kinase inhibitors on ET-1 and mechanical stretch-induced BNP gene expression. ERK inhibitor PD98059 (10 mM)
(A, D), p38 inhibitor SB203580 (10 mM) (B, E) or PKA inhibitor H89 (10 mM) (C, F) were added to culture medium of neonatal rat cardiomyocyte cell
cultures 2 hours prior to 1 h ET-1 stimuli (100 nM; A–C) or cyclic mechanical stretching (D–F). DMSO was used as a control. The mRNA levels were
normalized to 18S quantified from the same samples and the mRNA levels are presented relative to control cells. The results represent mean 6 SEM
(n = 8–18) from at least 3 independent experiments. *P,0.05; **P,0.01; ***P,0.001 compared to control.
doi:10.1371/journal.pone.0105168.g004
Activating Transcription Factor-3 in Cardiac Hypertrophy
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e105168
Activating Transcription Factor-3 in Cardiac Hypertrophy
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e105168
0.1 mM EGTA supplemented with protease-, phosphatase-inhib-
itor cocktail (1:100 volume), and 1 mM DTT (1:1000 volume).
Then, membrane proteins were solubilized and isolated by adding
10% IGEPAL CA-630 detergent. After centrifugation, the pellets
containing the nuclei were resuspended in high salt buffer
containing 20 mM HEPES, 0.4 M NaCl, 1 mM EDTA and
1 mM EGTA supplemented like the low salt buffer (see above).
The entire procedure was carried out at 4uC. Protein concentra-
tion of each sample was determined with Bio-Rad Protein Assay
(Bio-Rad Hercules, CA, USA). The double-stranded synthetic
oligonucleotides for electrophoretic mobility shift assay (EMSA)
containing binding sequences for NF-kB or AP-1 at BNP
promoter, Nkx-2.5 at ANP promoter and ATF3 binding site at
macrophage inflammatory protein 21b promoter were labelled
with [a-32P]-dCTP as described earlier [12]. The sequences used
for the EMSA probes are provided in Table 1. ATF3 binding
activity was determined with 24-bp double-stranded DNA
oligonucleotide probes containing the ATF3 binding site, previ-
ously shown to be a consensus binding site 59-TGACGTAC
A
G-39
[24,25]. To confirm DNA sequence specificity of the protein DNA
complex formation, competition experiments with 1-, 10-, and
100-molar excesses of non-radiolabeled (‘‘cold’’) ATF3 oligonu-
cleotides with intact or mutated binding sites were performed. For
competition and supershift experiments appropriate oligodeox-
ynucleotides or antibodies were added to reaction mixture 20 min
before addition of labeled probe. After electrophoresis the gels
were dried and exposed to PhosphorImager screens (Molecular
Dynamics, Sunnyvale, CA), which were then scanned using Bio-
Rad Molecular Imager FX Pro Plus (Bio-Rad Laboratories). All
the results were quantified using the Quantity One software.
Isolation and analysis of RNA
Total RNA from left ventricular tissue was isolated by the
guanidine thiocyanate-CsCl method and from cultured cardiomy-
ocytes with TRIzol Reagent according to the manufacturer’s
protocol (Invitrogen) by using Phase Lock Gel system (Eppendorf
AG, Hamburg, Germany) [21]. Rat ATF3, BNP, ANP, IL-6, PAI-
1, osteopontin (OSP), bone morphogenetic protein-2 (BMP-2) and
ribosomal 18S mRNA levels were measured by real-time RT-
qPCR as previously described [12]. The primers and fluorogenic
probes used are listed in Table 2. The results were normalized to
18S quantified from the same samples and then to control values.
Protein Synthesis
[4,5-3H] leucine incorporation was measured as previously
described [20]. Briefly, cells were cultured in 24-well plates. When
appropriate, the cells were transduced with recombinant adeno-
viruses. Subsequently the culture medium was supplemented with
[4,5-3H] leucine (5 mCi/ml). After 24 h, cells were lysed and
processed for measurement of incorporated [4,5-3H] leucine by
liquid scintillation counter.
Statistical analysis
The results are expressed as mean 6 SEM. To determine the
statistical difference between two groups, Student’s t-test was used.
For multiple comparisons, the results were analyzed with one-way
analysis of variance (ANOVA) followed by a least significant
difference (LSD) post hoc test. Differences at or above the 95%
level were considered statistically significant.
Results
ATF3 gene expression is rapidly activated in response to
ET-1 and mechanical stretch
First, to directly examine the effect of hypertrophic stimuli on
cardiomyocyte ATF3 expression, we treated NRCM with a panel
of hypertrophic agonists in vitro. In agreement with previous
studies showing that ET-1 activates ATF3 in NRCM [17,18], ET-
1 (100 nM) substantially increased ATF3 gene expression with
maximal mRNA levels at 1 hour(16.6–fold; P,0.001), returning
to almost basal levels within 4 hours (Figure 1A), while the
increase in ATF3 protein levels was sustained up to 4 hours
(Figure 1B). Furthermore, ATF3 mRNA levels were rapidly
increased in response to cyclic mechanical stretching; the levels
were highest (4.1–fold; P,0.001) at 1 h and remained significantly
elevated also following 4- and 24-hours of stretch (Figure 1C).
BNP mRNA levels, measured to validate hypertrophic response
[22], were increased in response to both ET-1 (Figure 1D) and
stretch (Figure 1E). Finally, when NRCM were treated with LPS
(1 mg/ml), an increase in ATF3 mRNA levels was noted
(Figure 1F).
The effect of kinase inhibitors on ET-1-induced ATF3
activation
Next, intracellular signaling pathways mediating ET-1 –induced
ATF3 activation were studied in NRCM. ET-1 is a potent
vasoconstrictor but also a pro-hypertrophic factor which is
synthesized and secreted in response stretching of cardiomyocytes
[26]. Similarly to mechanical stretch, ET-1 has been reported to
induce activation of Raf-1 and MAPKs as well as protein kinases
through the ETA receptor, leading to higher protein synthesis and
enlarged cell surface [26]. NRCM were exposed to kinase
inhibitors SB203580 (10 mM), PD98059 (10 mM) or H89 (1 mM)
[20,23,27]. Then, the cells were treated with 100 nM ET-1 for
1 hour. Neither PD98059 (Figure 2A), SB203580 (Figure 2B) nor
H89 (Figure 3A) had significant effect on ET-1 –induced increase
in ATF3 mRNA levels in NRCM. On the other hand, ET-1 –
induced ATF3 protein expression was reduced by ERK inhibitor
PD98059 (Figure 2C) and PKA inhibitor H89 (Figure 3B),
indicating the involvement of posttranscriptional mechanisms,
whereas a non-significant reduction was observed with p38
inhibitor SB203580 (Figure 2D). A higher dose of the PKA
inhibitor H89 (10 mM, [27]) significantly decreased ET-1 –
induced ATF3 mRNA expression (Figure 3C) and completely
abolished increase in ATF3 protein levels (P,0.001; Figure 3D).
Therefore, the PKA activator and b-receptor agonist isoprenaline
Figure 5. The effect of kinase inhibitors on mechanical stretch–induced increase in ATF3 expression. ERK inhibitor PD98059 (A, D), p38
inhibitor SB203580 (B, E) or PKA inhibitor H89 (C, F) were added at the concentration of 10 mM each. DMSO was used as a control. Approximately
2 hours after the insertion of inhibitors or DMSO, the cell cultures were subjected to cyclic mechanical stretching for 1 hour. ATF3 mRNA levels were
determined by RT-qPCR and normalized to 18S quantified from the same samples (A–C). The mRNA levels are presented relative to non-stretched
DMSO control cells. The results represent mean6 SEM (n= 2–19) from at least 3 independent experiments. The expression levels of ATF3 protein and
GAPDH loading control were detected by Western blotting (D–F). Representative Western blots are shown. ATF3 protein levels were normalized with
GAPDH levels and are presented relative to non-stretched DMSO control cells. Bar graphs represent mean 6 SEM (n= 4–12) from at least 3
independent experiments. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0105168.g005
Activating Transcription Factor-3 in Cardiac Hypertrophy
PLOS ONE | www.plosone.org 9 August 2014 | Volume 9 | Issue 8 | e105168
Figure 6. p38a MAPK regulates ATF3 activity. Cultured cardiomyocytes were transduced with recombinant adenoviruses WT p38a, WT p38b,
MKK3b and/or MKK6b for 24 hours at the virus amount of 4 MOI (2+2 MOI in combinations). RT-qPCR with cDNA derived from mRNA of neonatal rat
cardiomyocyte cell cultures transduced with recombinant adenovirus combinations WT p38a+MKK3b, WT p38b+MKK6b or control virus LacZ (A–B).
ATF3 (A) or BNP (B) mRNA levels were normalized to 18S quantified from the same samples and the mRNA levels are presented relative to LacZ
Activating Transcription Factor-3 in Cardiac Hypertrophy
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[28] was applied to NRCM to study further the possible role of
adenylyl cyclase-cAMP-PKA pathway in ATF3 regulation. The
isoprenaline treatment significantly increased ATF3 protein
expression and this increase was completely abolished by PKA
inhibitor H89 (Figure 3E). Moreover, as reported previously [28],
ET-1-induced BNP mRNA transcription was blunted by all three
kinase inhibitors (Figure 4A–C).
Stretch-induced ATF3 activation is attenuated by PKA
pathway –inhibitor
Next, the effect of kinase inhibitors on mechanical stretch-
induced ATF3 expression was studied in NRCM. Neither ERK
inhibitor PD98059 (Figure 5A) nor p38 MAPK inhibitor
SB203580 (Figure 5B) diminished stretch-activated increase in
ATF3 mRNA levels at one hour. Instead, ERK inhibition
abrogated the stretch-induced increase of ATF3 protein levels
(Figure 5D) and p38 inhibitor resulted in a similar trend
(Figure 5E). Moreover, H89 attenuated one-hour mechanical
stretch-induced increase in ATF3 mRNA levels (Figure 5C) and
completely abolished stretch-induced increase in ATF3 protein
expression (Figure 5F). All kinase inhibitors significantly decreased
the mechanical stretch-induced BNP gene expression (Figure 4D–
F), indicating that the time point and dose of the inhibitors used in
these experiments were sufficient to reduce stretch-induced gene
expression in cardiomyocyte cultures.
ATF3 activation is distinctly regulated by the two p38
MAPK isoforms
Since we have previously observed that ATF3 is a target gene of
p38a MAPK [12][29], we next examined possible differences
between the two main cardiac p38 isoforms, p38a and p38b, in
regulation of ATF3 activation. In view of previous observations
[20,30], cardiomyocyte cell cultures were transduced with
recombinant adenoviruses coding WT p38a and WT p38b along
with their constitutively active upstream kinase MKK3b and
MKK6b, respectively. ATF3 mRNA levels were significantly
increased by p38a+MKK3b overexpression, while p38b+MKK6b
had no significant effect on ATF3 gene expression (Figure 6A).
BNP mRNA levels were in turn significantly enhanced by p38b+
MKK6b and not by p38a+MKK3b (Figure 6B), as previously
shown [20]. ATF3 protein expression was also increased in
response to p38a +MKK3b (Figure 6C). The p38b isoform
markedly increased ATF3 protein expression although it was not
statistically significant (Figure 6D). Finally, to investigate whether
the higher ATF3 protein levels are associated to higher amount of
protein capable of binding a consensus ATF3 target binding site,
we performed an EMSA assay. As shown in Figure 6E, ATF3
DNA binding activity was promoted in response to p38a+MKK3b
and to lesser extent with p38b+MKK6b.
Role of ATF3 in the regulation of cardiomyocyte
hypertrophy
To investigate the role of ATF3 in hypertrophic process, we
used gain-of-function approach and overexpressed ATF3 in
NRCM by adenoviral transfection. The adenovirus- mediated
ATF3 gene delivery markedly increased ATF3 protein levels at the
virus amounts of 2, 4 and 8 MOI (Figure 7A) and ATF3 mRNA
levels were also significantly increased in response to adenoviral
ATF3 overexpression (Figure 7B). Of note, the molecular weight
of endogenous ATF3 (for example, see Figure 1B) was similar to
ATF3 produced by adenovirus-mediated gene delivery. Interest-
ingly, the expression of natriuretic peptides ANP (Figure 7C) and
BNP (Figure 7D) were not altered by the overexpression of ATF3.
Furthermore, another hallmark feature of cardiomyocyte hyper-
trophy, the rate of protein synthesis [31], was slightly but
significantly decreased (25.3%, P,0.05) in response to ATF3
overexpression, as measured by radioactively labeled leucine ([3H]
leucine) incorporation assay (Figure 7E).
To determine whether ATF3 has a role in hypertrophic
response in vivo, ATF3 was overexpressed by using adenovirus-
mediated gene delivery in normal adult rat heart for 3 days. This
time point was chosen because our previous time-course studies
indicated that the maximal up-regulation of target gene expression
is observed at day 3 after gene transfer [12]. ATF3 mRNA levels
were increased 15.0-fold in response to adenoviral ATF3
overexpression at three days following injections (Figure 8A). On
the other hand, ATF3 adenoviral gene transfer in vivo had no
effect on the gene expression of the several cardiac hypertrophy
markers, including ANP, BNP, a-MHC, and ß-MHC, and skeletal
and cardiac a-actins (Figure 8B) or the structure and function of
the heart, as analyzed by echocardiography (Table 3).
ATF3 overexpression down-regulates inflammation–
related genes
ATF3 has been proposed to be involved in the cardiac
inflammatory response [16,17]. Since we observed only a modest
effect on the hypertrophic response, the possible role of ATF3 as a
regulator of inflammation was explored by investigating the effect
of increased ATF3 on the expression of IL-6, PAI-1, OSP and
BMP-2 genes. All these genes represent important mediators in
cardiac pathology, mainly in inflammation and remodeling
process [32–34]. In agreement with previous studies [16,17],
ATF3 overexpression in cultured NRCM significantly reduced IL-
6 mRNA levels (Figure 7F). Also PAI-1 mRNA levels were
decreased (Figure 7G), while OSP (Figure 7H) and BMP-2
mRNA (Figure 7I) levels remained unchanged. Importantly,
overexpression of ATF3 in vivo resulted in a significant decrease
in PAI-1 mRNA levels (Figure 8C), although it had no effect on
IL-6 mRNA levels (Figure 8D). This may be due to different
experimental conditions (neonatal versus adult cells). It should be
noted that in vitro changes occurring to a single cell type were
studied, while in vivo cardiomyocytes co-exist with other cell
populations.
Overexpression of ATF3 results in increase in Nkx-2.5 and
NF-kB DNA binding activities
Since our results indicate that ATF3 modulates rather
inflammatory than hypertrophic factors, we investigated the effects
of ATF3 overexpression on DNA binding activity of transcription
factors known to be involved in the regulation of inflammatory
control cells. The results represent mean 6 SEM (n= 6–8) from 4 independent experiments. Western blot analysis of cell lysate derived from NRCM
cultures transduced with WT p38a and MKK3b (C) or WT p38b and MKK6b (D) recombinant adenoviruses. ATF3 and GAPDH protein levels were
detected by Western blotting and representative Western blots are shown. ATF3 protein levels were normalized with GAPDH levels and are presented
relative to LacZ control. Bar graphs represent mean 6 SEM (n= 6) from 3 independent experiments. EMSA of nuclear protein from adenovirus–
transduced cultured cardiomyocytes (E). ATF3 antibody (2 ml) causes supershift reaction (representative blot is shown) and ATF3 binding activity in
response to WT p38a+MKK3b and WT p38b+MKK6b is presented as bar graphs (mean 6 SEM, n = 12–13 from 3 independent experiments) and
representative blot. * P,0.05; **P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0105168.g006
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Figure 7. The effect of ATF3 overexpression in vitro on hypertrophy and inflammatory markers. Representative Western blot analysis of
cell lysate derived from cultured NRCM transduced with recombinant adenoviruses overexpressing ATF3 or control virus LacZ at the virus amounts of
2, 4, and 8 MOI (A). The expression level of ATF3 (upper panel) and GAPDH loading control (lower panel) from one representative Western blot
(performed in triplicates) is shown. RT-qPCR analysis with cDNA derived from mRNA of NRCM cultures transduced with recombinant adenovirus ATF3
or control virus LacZ (B–D, F–G). ATF3 (B), ANP (C), BNP (D), IL-6 (F), PAI-1(G), OSP (H), and BMP-2 (I) mRNA levels are normalized to 18S quantified
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genes such as NF-kB, Nkx-2.5 and AP-1 transcription factors. The
cardiomyocyte nuclear extracts exhibited specific binding activity
on ATF3 binding site; the formation of complexes with the ATF3
probe was dose-dependently inhibited by the non-radiolabeled
ATF3 dsDNA oligonucleotides with intact binding site, but not by
the oligonucleotides with mutated binding site, and supershift
analysis showed antibody-induced supershift of the ATF3 complex
(Figure 9A). ATF3 binding activity was elevated 35.6% (P,0.001)
in response to ATF3 overexpression (Figure 9B) further indicating
that the ATF3 produced by adenovirus-mediated gene delivery
was functional. Importantly, the DNA binding activities of NF-kB
(Figure 9C) and Nkx-2.5 (Figure 9D) were significantly increased
in response to ATF3 overexpression, whereas AP-1 binding
activity was not changed (Figure 9E). As a control experiment for
increased ATF3 DNA binding, we studied the changes in ATF3
binding activity in response to ET-1 stimulation. ET-1-insertion
into culture medium augmented ATF3 binding activity by 31.8%
at 1 h and this increase was sustained at 4 h, 12 h and 24 h time-
points (Figure 9F).
Discussion
Myocardial hypertrophy can be induced by pressure or volume
overload, and also by a number of neurohumoral factors,
including ET-1, angiotensin II, noradrenaline [31], and isopren-
aline [13]. In vitro mechanical stretch provides a reliable model
whose effects on cardiomyocytes resembles those of cardiac
pressure overload-induced cardiac hypertrophy in vivo. ATF3 is
an immediate early gene (IEG), which is typically induced by
growth factors or various stress signals [35] suggesting that it may
be a key regulator in cellular stress responses. It is assumed that
rapid and transient induction of IEGs such as ATF3, c-fos,c-jun
and EGR-1 regulate the expression of other hypertrophic genes
[17,36]. This study demonstrates that ATF3 is substantially
activated in response to ET-1 treatment, in agreement with
previous studies [16,17]. Furthermore, ET-1 stimulation signifi-
cantly increased ATF3 DNA binding activity, detected by EMSA.
Our results also for first time demonstrate that ATF3 is potently
and rapidly (within 1 hour) activated by direct mechanical stretch
of cardiomyocytes.
from the same samples and presented relative to LacZ control cells. The results represent mean 6 SEM (n= 27–32) from 3- 4 independent
experiments. [3H]leucine (5 mCi/ml) was inserted to culture medium of NRCM transduced with recombinant adenovirus ATF3 or control virus LacZ at
the concentration of 4 MOI, and incorporated [3H]leucine was detected by liquid scintillation counter (E). The results represent mean 6 SEM (n = 32)
from 3 independent experiments. *P,0.05; ***P,0.001.
doi:10.1371/journal.pone.0105168.g007
Figure 8. In vivoATF3 overexpression downregulates the gene expression of PAI-1. Three days following the adenoviral injection of ATF3
or LacZ (16109 pfu) into the left ventricular wall of adult rats, the animals were sacrificed and mRNA was extracted and cDNA synthesized for RT-qPCR
analysis. ATF3 (A), ANP, BNP, a- and ß-MHC, cardiac and skeletal a-actins (B), PAI-1 (C) and IL-6 (D) mRNA levels were normalized to 18S quantified
from the same samples and presented relative to LacZ-injected animals. The results are mean 6 SEM (n = 4–5). *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0105168.g008
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The involvement of JNK pathway in the regulation of ATF3
activation in various cells is well established [37–39], whereas the
role of ERK is more controversial; it has been shown to function as
a positive regulator of ATF3 in human colorectal cancer cells [40]
and negative regulator of TNFa (tumor necrosis factor a) -
mediated induction of ATF3 in vascular endothelial cells [38].
Moreover, the inhibition of ERK pathway by PD98059 had no
effect on anisomycin-induced ATF3 activation and overexpression
of ERK or upstream activator MKK1 did not increase the ATF3
transcription in HeLa cells [41]. Here we show that the inhibition
of ERK pathway with MKK1 inhibitor PD98059 attenuated the
ET-1– and stretch-induced ATF3 protein expression but not
ATF3 mRNA transcription. These data indicate that ERK
regulates ATF3 transcription through posttranscriptional modifi-
cations. The inhibition of p38 MAPK by SB203580 had only a
modest and statistically non-significant effect on ATF3 protein
levels and no effect on ATF3 mRNA level, thus implicating that
inhibiting p38 does not significantly impair ET-1– or stretch-
induced ATF3 activation.
Our results further demonstrate that the PKA inhibitor H89 is
able to prevent the ET-1- and mechanical stretch– induced ATF3
gene and protein expression in NRCM. Interestingly, a study
showed that ATF3 overexpression in cardiomyocytes diminished
phospholamban (PLB) promoter activation [42]. PLB in turn, is a
target of PKA-mediated phosphorylation leading to enhanced
systolic Ca2+ concentrations improving cardiac contractility [28].
Although the selectivity of H89 as PKA inhibitor has been argued
[43,44], H89 is still widely used as PKA inhibitor [27,45]. Our
results show that H89 prevents ATF3 mRNA expression also in
the presence of isoprenaline, a more specific PKA activator known
to activate ATF3 [13]. Thus, it can be hypothesized that ATF3
might play a role in PKA-mediated regulation of cardiac muscle
contractility. Consistent with this, ATF3 is also induced by
adenylyl cyclase VI overexpression in cardiomyocytes [42].
Even though we observed a very modest effect of p38 MAPK
route blockade on ATF3, our previous DNA microarray study
demonstrated that p38a MAPK overexpression with MKK3b
induced ATF3 mRNA expression 7.7-fold [12]. Therefore, we
characterized in detail the possible differences between the two
main p38 isoforms in the heart, p38a and p38b, in the regulation
of ATF3. Notably, upstream kinase MKK6, which is 80%
homologous to MKK3, can activate all four p38 isoforms (p38a,
p38b, p38c, and p38d), whereas MKK3 preferentially activates
only p38a, p38c, and p38d [30]. We have previously reported
significant differences in the downstream targets of p38a and p38b
[20]. Here we show that p38a isoform overexpression in
combination with MKK3 increased ATF3 mRNA and protein
expression as well as ATF3 DNA binding activity. Taken together,
the regulation of ATF3 by p38 pathways is isoform specific, since
only p38a overexpression was able to activate ATF3.
Although ATF3 gene expression has been consistently reported
to be induced in ischemic and ischemia/reperfusion-treated hearts
in vivo and in vitro [10,11,39], the role of ATF3 in cardiovascular
pathology is unclear. Transgenic mice expressing ATF3 under the
control of the a-myosin heavy chain promoter exhibited both
atrial enlargement and ventricular hypertrophy as well as myocyte
degeneration, extensive fibrosis of the heart wall, conduction
abnormalities and contractile dysfunction [18,19], indicating that
ATF3 is detrimental stress-inducible gene. In contrast, Nobori et
al. demonstrated cardioprotective effects of the acute induction of
ATF3 [46]. In addition, more recent studies using loss-of-function
approaches resulted in impaired hypertrophic response in vitro
[16,17] while in vivo it revealed promotion of cardiac hypertro-
phy, dysfunction and fibrosis [15]. Here we show that the
overexpression of ATF3 did not affect the gene expression of
cardiac hypertrophy markers such as the natriuretic peptides ANP
and BNP, a- and b-MHC, or cardiac and skeletal a-actin isoforms.
Both ANP and BNP are rapidly induced during mechanical
loading of cardiomyocytes both in vitro and in vivo and highly
expressed in hypertrophied left ventricles [3,47]. Moreover, the
rate of protein synthesis, another important hallmark of patho-
logical cardiac hypertrophy, was not increased but even slightly
decreased in response to ATF3 overexpression. Thus, although
ATF3 was induced by hypertrophic stimuli, the ATF3 activation
was not coupled with the central elements of pathological left
ventricular hypertrophy – induction of hypertrophic genes and
Table 3. Echocardiography, and body and left ventricular weight data of ATF3 adenovirus-mediated gene delivery in normal adult
rat heart compared to LacZ control.
Variable LacZ ATF3 P-value
IVS(diastole, mm) 2.060.1 1.860.1 0.151
LV (diastole, mm) 7.760.3 7.460.1 0.524
LVPW (diastole, mm) 1.660.1 1.860.1 0.561
Fractional shortening (%) 36.660.7 34.160.1 0.268
Ejection fraction (%) 72.060.9 68.660.1 0.239
LV IVRT 22.561.4 25.860.1 0.083
HR 28669 27060.1 0.213
LV mass (mg) 1027648 97060.1 0.588
Body weight T0 (g) 27467 25660.1 0.125
Body weight T3 (g) 28169 25960.1 0.084
BW T3-T0 (g) 765 360.1 0.511
LV mass/BW (mg/g) 3.760.2 3.860.4 0.913
Adenoviral gene construct expressing ATF3 and LacZ were injected onto the LV free wall and echocardiographic measurements were performed at 3 days after gene
transfer. The values are expressed as mean 6 SEM (n = 5–6/group).
P-values are the result of ATF3 vs. LacZ Student’s t-test.
IVS, interventricular septum; LV, left ventricle; LVPW, left ventricular posterior wall; IVRT, isovolumetric relaxation time; HR, heart rate; BW, body weight.
doi:10.1371/journal.pone.0105168.t003
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Figure 9. ATF3 overexpression induces the binding activity of NF-kB and Nkx-2.5. Representative EMSA blot of nuclear protein from
cultured NRCM (A). ATF3 antibody (2 ml) caused supershift reaction (upper panel) and non-radiolabeled ATF3 probe (self) competes with radiolabeled
ATF3 for binding to the probe, whereas mutated non-radiolabeled ATF3 probe (mut) had no effect (lower panel). EMSA of nuclear protein from ATF3
or LacZ adenovirus transduced (for 24 hours at the virus amount of 4 MOI) cultured cardiomyocytes (B–E). ATF3 (B), NF-kB (C), Nkx-2.5 (D) and AP-1
(E) binding activities are presented as bar graphs (mean6 SEM, n = 9–15 from at least 3 independent experiments) and representative blots. Also NF-
kB (C), Nkx-2.5 (D) and AP-1 (E) antibodies (2 ml) cause supershift reactions (representative blots are shown). ET-1 stimulates ATF3 binding activity in
cardiomyocytes (F). EMSA of nuclear protein from cultured cardiomyocytes treated with ET-1 (100 nM) for 1, 4, 12 and 24 hours. ATF3 binding activity
is presented as bar graphs (mean 6 SEM, n= 8 from 3 independent experiments) and representative blot. *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0105168.g009
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increased rate of protein synthesis – suggesting that the role of
ATF3 in stressed cardiac myocytes might in fact be beneficial
[15,17].
NF-kB repression has been shown to rescue cardiac function
and improve survival during cardiac inflammation through
decreased apoptosis [8]. NF-kB is also a central regulator of
cardiac hypertrophy and it controls the expression of IEGs as well
as stress-responsive genes in many cell types [8]. For example, it
has been shown that NF-kB mediates both isoprenaline- and
angiotensin II–induced cardiac hypertrophy and inflammation in
vivo [48]. Nkx-2.5 transcription factor, in turn, is a critical
regulator of cardiac development and suggested to participate in
cardiac hypertrophic response through its known ability to interact
with other cardiac transcription factors such as GATA4 and serum
response factor (SRF) [8]. Previously it has been shown that PE
and isoprenaline–induced hypertrophic response is partly mediat-
ed through Nkx-2.5 [49]. Accumulated evidence also indicates
that Nkx-2.5 functions as a survival factor for cardiomyocytes [8].
Using EMSA, we demonstrated in the current study that ATF3
overexpression increased DNA binding activity of NF-kB and
Nkx-2.5, while the binding activity of AP-1, transcription factor
mainly related to pathological cardiac hypertrophy [7,50],
remained unchanged. Taken together, these data support the
hypothesis that ATF3 is involved in an adaptive hypertrophic
response through activation of NF-kB andNkx-2.5.
In addition to hypertrophy, myocardial fibrosis plays a key role
in development of heart failure [1,2]. Fibrosis involves the
accumulation of collagens I and III in the myocardium and the
activation of numerous pro-fibrotic molecules such IL-6 and PAI-
1, as well as vasoactive substances angiotensin II and ET-1
[16,17]. It has been previously demonstrated that ATF3 is a
potential repressor of ET-1–induced IL-6 activation, and an ATF3
consensus sequence is present in rat IL-6 promoter [16,17,51]. IL-
6 is an inflammation-associated gene elevated in pathological
hypertrophy, and the elevation of IL-6 has been linked to the
development of heart failure [52]. PAI-1, in turn, is a member of
serine protease inhibitor superfamily, shown to play a key role in
the regulation of proteolytic degradation of the extracellular
matrix during cardiac remodelling process [53]. IL-6 has been
shown to be up-regulated by p38a overexpression in vivo [12] and
PAI-1 by angiotensin II infusion in vivo [53]. In contrast, ATF3
knockdown in ET-1 stimulated cardiomyocytes had no effect on
increase in expression of IL-6, suggesting that ATF3 regulates IL-6
through interaction with NF-kB rather than ERKK, which is up-
regulated by ET-1 stimuli [17]. In adult mice, IL-6 and other
inflammatory markers were increased due to ATF3 expression
[18]. We observed here that IL-6 gene expression is significantly
decreased in vitro in response to ATF3 overexpression, as reported
previously [12]. In addition, ATF3 overexpression significantly
diminished PAI-1 gene expression both in vivo and in vitro,
suggesting an anti-fibrotic function for ATF3. On the other hand,
the levels of two other markers of cardiac pathology, BMP-2 and
osteopontin OSP [33,54] remained unchanged in response to
ATF3 activation. Collectively, these studies are consistent with the
role of ATF3 as hypertrophic stimuli -inducible transcriptional
repressor of gene expression [10,55].
In conclusion, our present findings demonstrate that ATF3
transcription and DNA binding activity are up-regulated by
hypertrophic stimuli in vitro. A number of signalling pathways are
activated in cardiomyocytes after stress stimuli, and our results
demonstrate ATF3 activation is partly mediated through ERK,
PKA and p38a but not p38b. Finally, our observations support a
cardioprotective role for ATF3 through induction of survival
factor Nkx-2.5, and through attenuation of pro-fibrotic and pro-
inflammatory proteins IL-6 and PAI-1. Our results, in combina-
tion with previous studies, indicate that ATF3 is involved in an
adequate early response to stress-stimuli in heart and suggest that
dysregulation of ATF3 signal transduction might contribute to
maladaptive response and, therefore, to the development of heart
failure.
Limitations
One limitation in evaluating the effects of hypertrophic stimuli
in cardiomyocytes was that we did not explore the possibility of
changes in the subcellular localization of ATF3, possibly
explaining differences between ATF3 mRNA expression and
protein levels. Furthermore, cardiomyocyte-specificity of the
adenovirus-mediated gene delivery in vivo was not assessed, and
thus we cannot rule out the possibility of the effects of other cell
populations. In addition, to reveal the long-term structural and
functional effects of ATF-3 overexpression, the experiments with
long term follow-up are needed.
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